As per enclosed intimation letter.
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Divis Laboratories reported strong FY2025-26 results with consolidated total income of Rs 11,067 crores (up 13.9% from Rs 9,712 crores). Standalone PAT grew 18% to Rs 2,607 crores while consolidated PAT rose 17.2% to Rs 2,568 crores. Q4 standalone revenue was Rs 2,793 crores with PAT of Rs 756 crores, both showing double-digit growth versus Q4 FY25. The company recognized Rs 74 crores as exceptional item due to new Indian labour codes impact on employee benefits. Forex gains contributed Rs 210 crores for the full year (vs Rs 48 crores prior year). The Board recommended a dividend of Rs 30 per share (1500% on face value Rs 2). Statutory auditors issued unmodified opinion on both standalone and consolidated financial statements.
Strong financial performance with 17-18% PAT growth demonstrates operational efficiency. The generous 1500% dividend signals management confidence. Shareholders can expect positive market sentiment given robust cash flows of Rs 2,711 crores from operations and clean audit findings.